Breaking News, Collaborations & Alliances

RuiYi, Genor to Develop Autoimmune Antidody

RYI-008 has the potential to treat autoimmune diseases and cancer

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

RuiYi, Inc. has entered into an exclusive license and collaboration agreement with Genor BioPharma for the development of RYI-008 in China. RYI-008 is a novel anti-IL-6 monoclonal antibody with a unique pharmacologic profile that has the potential to treat autoimmune diseases and cancer.   “RYI-008, with its unprecedented femtamolar potency and amazing long half-life has a therapeutic profile of once monthly, low milligram, subcutaneous dosing,” said Paul Grayson, president and chief...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters